Pre-Emptive Parecoxib Sodium for Pain Control During CT-Guided Lung Nodule Localization
NCT07675473 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150
Last updated 2026-06-30
Summary
Before undergoing minimally invasive lung surgery, patients with small lung nodules often need a procedure called "CT-guided hook wire localization." This involves using a CT scanner to help doctors place a tiny wire in the lung to mark the exact location of the nodule for the surgeon. While very helpful for the surgery, this wire placement can be highly painful for patients.
The main purpose of this clinical trial is to find out if giving patients a pain-relieving medication called parecoxib sodium before the procedure can effectively reduce their pain. Parecoxib sodium is a standard, non-opioid painkiller given through an IV.
Additionally, researchers want to discover the best time to give this medication. Because operating room schedules can change, patients will receive the IV medication at different times before their localization procedure (ranging from less than an hour to more than 3 hours beforehand). By looking at these different wait times, researchers hope to identify the "golden window"-the exact timing that provides the most pain relief.
During the study, participants will be randomly assigned by a computer to one of two groups:
The Study Group: Will receive the active pain medication (parecoxib sodium).
The Control Group: Will receive a placebo (a saltwater solution with no active medicine).
To ensure the results are fair and unbiased, participants have a 2 in 3 chance of receiving the active medication, and neither the patients nor their doctors will know which assignment they received. Immediately after the wire is placed, participants will be asked to rate their pain on a scale of 0 to 10.
By comparing the pain scores between the two groups and looking at the different medication timings, researchers hope to create better, more comfortable care guidelines for future lung surgery patients.
Conditions
- Lung Nodules
Interventions
- DRUG
-
PARECOXIB SODIUM
40mg administered intravenously prior to CT-guided hook wire localization.
- DRUG
-
0.9 % Normal Saline
Visually identical 0.9% normal saline administered intravenously prior to CT-guided hook wire localization.
Sponsors & Collaborators
-
Long Jiang
lead OTHER
Principal Investigators
-
Long Jiang, M.D. & Ph.D. · Shanghai Chest Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-06-01
- Primary Completion
- 2028-06-15
- Completion
- 2028-06-15
Countries
- China
Study Locations
More Related Trials
-
PRA-216 COPD Safety and Biomarker Study
NCT07730281 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of 9MW3811 in Healthy Subjects
NCT05740475 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I/IIa Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
NCT05468502 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT01266135 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis
NCT03287414 ·Status: TERMINATED ·Phase: PHASE2
-
Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis
NCT07728721 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis
NCT05130970 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
NCT07121413 ·Status: RECRUITING ·Phase: PHASE2
-
SB17170 Phase 2 Trial in IPF Patients
NCT06747923 ·Status: RECRUITING ·Phase: PHASE2
-
To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF
NCT05497284 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis
NCT05349760 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of Single and Multiple Oral Doses of SCB0020160 in Healthy Adult Male Subjects
NCT07682337 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPF
NCT05016817 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
NCT02648048 ·Status: COMPLETED ·Phase: PHASE1
-
Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
NCT01266317 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
NCT05570058 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19
NCT04338802 ·Status: UNKNOWN ·Phase: PHASE2
-
Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)
NCT04370873 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
NCT07036523 ·Status: RECRUITING ·Phase: PHASE2
-
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT02707640 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Clinical Study of the Pulsed Electric Field Ablation System in Chronic Obstructive Pulmonary Disease
NCT07068438 ·Status: RECRUITING ·Phase: NA
-
Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP.
NCT01983657 ·Status: UNKNOWN ·Phase: PHASE2
-
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
NCT05612035 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2